ECElena Solfaroli Camillocci

Elena Solfaroli Camillocci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena Solfaroli Camillocci has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Optimizing Glomerular Filtration Rate Estimation: A Simplified Method for Improved Accuracy and Efficiency

    by Elena Solfaroli Camillocci, Davide Ciucci, Claudia Polito, Salvatore Donatiello, Antonio Napolitano, Damiano Palmieri, Luigi Rinaldi, Andrea Apollonio, Maria Felicia Villani, Milena Pizzoferro, et al.

    The glomerular filtration rate (GFR) is a key measure of renal function, typically estimated using creatinine-based equations. More precise clearance measurements are obtained with radiotracers, such as [99mTc]Tc-diethylenetriaminepentaacetic acid (DTPA), and blood samples over several hours. However, standard plasma clearance methods require labor-intensive plasma preparation, limiting efficiency in clinical practice. This study proposes a simplified approach to GFR estimation by directly measuring radioactivity in whole blood and applying a correction factor based on hematocrit, eliminating the need for blood centrifugation and reducing calibration steps. Methods: Sixty-seven adults and children undergoing GFR assessment with [99mTc]Tc-DTPA were included in the study. GFR was estimated using both the standard plasma-based method and a whole-blood approach, which directly measured radioactivity in whole blood and applied a correction factor based on hematocrit. The γ-counter’s response linearity and reproducibility were assessed to validate the correction factor. Comparisons between plasma-based and whole blood–derived GFRs were performed using linear regression and deviation analysis. Results: The γ-counter demonstrated a detection efficiency of 50.5% in the activity range of 30–150 kBq, confirming its reliability for whole-blood measurements. The proposed whole-blood method yielded GFRs that were highly correlated with the plasma-based approach, with an average deviation of 4%. Significant deviations (>15%) were observed in only 2 of 67 cases. The whole-blood method eliminated the need for plasma separation, reduced processing time, and maintained measurement accuracy. Conclusion: The proposed whole-blood approach provides a reliable alternative to standard plasma-based GFR estimation, simplifying sample preparation and reducing clinical workload. This method enhances efficiency in nuclear medicine while preserving measurement accuracy, making it a viable option for routine renal function assessment. Visual Abstract

  • Reconstruction of time-activity curves in molecular radiotherapy using a Bayesian unfolding

    by F. Nicolanti, L. Arsini, L. Campana, F. Collamati, R. Faccini, R. Mirabelli, S. Morganti, E. Solfaroli Camillocci, C.MAncini Terracciano


  • Oral cavity damage as a potential health risk from germicidal UV lamp use in occupational and emergency situations

    by Vincenzo Camisa, Salvatore Zaffina, Elena Solfaroli Camillocci, Davide Ciucci, Gian Marco Contessa, Emanuele Coscia, Reparata Rosa Di Prinzio, Annapaola Santoro, Maria Rosaria Vinci, Massimo Borra, et al.


  • DEVELOPMENT OF A WEARABLE INDIVIDUAL DOSE MONITORING APPARATUS FOR INTERNAL DOSIMETRY IN TARGETED RADIONUCLIDE THERAPY

    by L. Campana, A. Ambrosino, B. Cassano, F. Collamati, R. Faccini, G. Iaccarino, C. Mancini Terracciano, R. Mirabelli, S. Morganti, F. Nicolanti, et al.

  • Open Access

    Evolution of Portable Sensors for In-Vivo Dose and Time-Activity Curve Monitoring as Tools for Personalized Dosimetry in Molecular Radiotherapy

    by Lidia Strigari, Raffaella Marconi, Elena Solfaroli-Camillocci

    Treatment personalization in Molecular Radiotherapy (MRT) relies on pre- and post-treatment SPECT/ PET-based images and measurements to obtain a patient-specific absorbed dose-rate distribution map and its evolution over time. Unfortunately, the number of time points that are available per patient to investigate individual pharmacokinetics is often reduced by limited patient compliance or SPECT or PET/CT scanner availability for dosimetry in busy departments. The adoption of portable sensors for in-vivo dose monitoring during the entire treatment could improve the assessment of individual biokinetics in MRT and, thus, the treatment personalization. The evolution of portable devices, non-SPECT/PET-based options, already used for monitoring radionuclide activity transit and accumulation during therapy with radionuclides (i.e., MRT or brachytherapy), is presented to identify valuable ones, which combined with conventional nuclear medicine imaging systems could be effective in MRT. External probes, integration dosimeters and active detecting systems were included in the study. The devices and their technology, the range of applications, the features and limitations are discussed. Our overview of the available technologies encourages research and development of portable devices and dedicated algorithms for MRT patient-specific biokinetics study. This would represent a crucial advancement towards personalized treatment in MRT.


  • PO-1578 WIDMApp, an innovative approach for individual dose monitoring in Molecular Radiotherapy

    by C. Mancini Terracciano, F. Collamati, R. Faccini, G. Iaccarino, R. Mirabelli, F. Nicolanti, M. Pacilio, A. Soriani, L. Campana, E. Solfaroli Camillocci

  • Open Access

    Technical note: A wearable radiation measurement system for collection of patient‐specific time‐activity data in radiopharmaceutical therapy: system design and Monte Carlo simulation results

    by Silvio Morganti, Francesco Collamati, Riccardo Faccini, Giuseppe Iaccarino, Carlo Mancini‐Terracciano, Riccardo Mirabelli, Francesca Nicolanti, Massimiliano Pacilio, Antonella Soriani, Elena Solfaroli‐Camillocci

    Purpose: A high level of personalization in Molecular Radiotherapy (MRT) could bring advantages in terms of treatment effectiveness and toxicity reduction. Individual organ‐level dosimetry is crucial to describe the radiopharmaceutical biodistribution expressed by the patient, to estimate absorbed doses to normal organs and target tissue(s). This paper presents a proof‐of‐concept Monte Carlo simulation study of “WIDMApp” (Wearable Individual Dose Monitoring Apparatus), a multi‐channel radiation detector and data processing system for in vivo patient measurement and collection of radiopharmaceutical biokinetic data (i.e., time‐activity data). Potentially, such a system can increase the amount of such data that can be collected while reducing the need to derive it via nuclear medicine imaging.Methods: a male anthropomorphic MIRD phantom was used to simulate photons (i.e., gamma‐rays) propagation in a patient undergoing aI thyroid treatment. The administered activity was set to the amount usually administered for the treatment of differentiated carcinoma while its initial distribution in different organs was assigned following the ICRP indications for theI biokinetics. Using this information, the simulation computes the Time‐dependent Counts Curves (TCCs) that would have been measured by seven WIDMApp‐like sensors placed and oriented to face each one of five emitting organs plus two thyroid lobes. A deconvolution algorithm was then applied on this simulated data set to reconstruct the Time‐Activity Curve (TAC) of each organ. Deviations of the reconstructed TACs parameters from values used to generate them were studied as a function of the deconvolution algorithm initialization parameters and assuming non‐Poisson fluctuation of the TCCs data points.Results: This study demonstrates that it is possible, at least in the simple simulated scenario, to reconstruct the organ cumulated activity by measuring the time dependence of counts recorded by several detectors placed at selected positions on the patient's body. The ability to perform in vivo sampling more frequently than conventional biokinetic studies increases the number of time points and therefore the accuracy in TAC estimates. In this study, an accuracy on cumulated activity of 5% is obtained even with a 20% error on the TCC data points and a 50% error on the initial guess on the parameters of the deconvolution algorithm.Conclusions: the WIDMApp approach could provide an effective tool to characterize more accurately the radiopharmaceutical biokinetics in MRT patients, reducing the need of resources of nuclear medicine departments, such as technologist and scanner time, to perform individualized biokinetics studies. The relatively simple hardware for the approach proposed would allow its application to large numbers of patients. The results obtained justify development of an actual prototype system to characterize this technique under realistic conditions.


  • Open Access

    Radioguided surgery with β− radiation in pancreatic Neuroendocrine Tumors: a feasibility study

    by Francesco Collamati, Daria Maccora, Sergio Alfieri, Valerio Bocci, Antonella Cartoni, Angela Collarino, Micol De Simoni, Marta Fischetti, Ilaria Fratoddi, Alessandro Giordano, et al.

    The possibility to use β− decaying isotopes for radioguided surgery (RGS) has been recently proposed, and first promising tests on ex-vivo samples of Meningioma and intestinal Neuroendocrine Tumor (NET) have been published. This paper reports a study of the uptake of 68Ga-DOTATOC in pancreatic NETs (pNETs) in order to assess the feasibility of a new RGS approach using 90Y-DOTATOC. Tumor and healthy pancreas uptakes were estimated from 68Ga-DOTATOC PET/CT scans of 30 patients with pNETs. From the obtained SUVs (Standardised Uptake Value) and TNRs (Tumor Non tumor Ratio), an analysis algorithm relying on a Monte Carlo simulation of the detector has been applied to evaluate the performances of the proposed technique. Almost all considered patients resulted to be compatible with the application of β−-RGS assuming to administer 1.5 MBq/kg of activity of 90Y-DOTATOC 24 h before surgery, and a sampling time of few seconds. In just 2 cases the technique would have required a mildly increased amount of activity or of sampling time. Despite a high physiological uptake of 68Ga-DOTATOC in the healthy pancreas, the proposed RGS technique promises to be effective. This approach allows RGS to find application also in pancreatic diseases, where traditional techniques are not viable.


  • Secondary radiation measurements for particle therapy applications: Charged secondaries produced by 16O ion beams in a PMMA target at large angles

    by A. Rucinski, G. Traini, A. Baratto Roldan, G. Battistoni, M. De Simoni, Y. Dong, M. Fischetti, P.M. Frallicciardi, E. Gioscio, C. Mancini-Terracciano, et al.


  • Open Access

    Radioguided surgery with β radiation: a novel application with Ga68

    by Francesco Collamati, Valerio Bocci, Paolo Castellucci, Micol De Simoni, Stefano Fanti, Riccardo Faccini, Alessandro Giordano, Daria Maccora, Carlo Mancini-Terracciano, Michela Marafini, et al.

    Radio Guided Surgery is a technique helping the surgeon in the resection of tumors: a radiolabeled tracer is administered to the patient before surgery and then the surgeon evaluates the completeness of the resection with a handheld detector sensitive to emitted radiation. Established methods rely on γ emitting tracers coupled with γ detecting probes. The efficacy of this technique is however hindered by the high penetration of γ radiation, limiting its applicability to low background conditions. To overtake such limitations, a novel approach to RGS has been proposed, relying on β− emitting isotopes together with a dedicated β probe. This technique has been proved to be effective in first ex-vivo trials. We discuss in this paper the possibility to extend its application cases to 68Ga, a β+ emitting isotope widely used today in nuclear medicine. To this aim, a retrospective study on 45 prostatic cancer patients was performed, analysing their 68Ga-PSMA PET images to asses if the molecule uptake is enough to apply this technique. Despite the expected variability both in terms of SUV (median 4.1, IQR 3.0–6.1) and TNR (median 9.4, IQR 5.2–14.6), the majority of cases have been found to be compatible with β-RGS with reasonable injected activity and probing time (5 s).